ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0210

Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0230

Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job Syndrome

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0001

Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis

(0001–0008) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 0593

Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: PP03

Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 0255

Lymphoid Mass in the Inferior Turbinate with IgG4 Producing Cells: A Nasal Manifestation of IgG4-RD or a Distinct Chronic Inflammatory Disease?

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0058

Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0026

Mapping Cellular Landscape of Esophageal Epithelium in Systemic Sclerosis Using Single-cell Transcriptomics

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0289

Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity

(0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0546

Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0184

Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE

(0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

9:00AM-11:00AM: Abstract Number: 0676

Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center

(0673–0690) Vasculitis – ANCA-Associated Poster I: Treatment Outcomes

9:00AM-11:00AM: Abstract Number: 0335

Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool

(0325–0344) Patient Outcomes, Preferences, & Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 0407

Meteorological Conditions Contribute to the Joint Ultrasound Findings in Patients with Rheumatoid Arthritis: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0254

Microvascular and Cutaneous Assessment in Adult Patients with Hypermobile Ehlers-Danlos Syndrome

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].